-
-
-
-
-
-
-
Day One Biopharmaceuticals (DAWN) Announces Publication of Tovorafenib FIREFLY-1 Data
-
-
-
-
-
-
-
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
-
-
-
-
-
-
-
Day One Announces Pricing of Public Offering of Common Stock
-
-
-
-
-
-
-
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
-
-
-
-
-
-
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
-
-
-
-
-
-
-
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
-
923,861 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All